RAD Radiopharm Theranostics Limited
Financings ·
Radiopharm amended its at-the-market program to $9,300,000 on July 23, 2026. The next day it announced a $4.1 million registered direct offering at $3.16 per ADS, below the $4.29 last sale price on July 21.
Radiopharm Theranostics filed a $50,000,000 shelf registration on December 16, 2025 and a sales agreement with Leerink Partners the same day. A prospectus supplement filed December 23 set up to $18,900,000 of at-the-market sales.
Radiopharm Theranostics Limited describes itself as a research and development company that aims to develop and commercialize platforms of radiopharmaceutical products for therapeutic and diagnostic applications in precision oncology. It says its technologies span peptides, small molecules and antibodies attached to medical quality radioisotopes, and it focuses on radiosensitive tumor types with high mortality rates. Its pipeline builds on licensed platform technologies, including exclusive rights from NanoMab Technologies to anti-HER-2, anti-TROP-2, anti-PD-L1 and anti-PTK7 technology, from TRIMT GmbH to the Ga-Trivehexin technology, and a license from Cancer Research Technology for the F-FPIA imaging agent. Through Pharma15, acquired in March 2023, it is developing next-generation therapeutic radiopharmaceuticals for prostate cancer that seek to overcome resistance to PSMA-targeting therapies. Lantheus is a shareholder and a development partner under a strategic development services contract to advance radiopharmaceuticals in Australia. AtomVie performs development and manufacturing services for 177Lu-BetaBart, a 177Lutetium-conjugated B7-H3 targeting radioantibody. Radiopharm Ventures, a joint venture with MD Anderson, is developing several clinical assets that are in the pre-clinical stage.
| Product or program | What it is | Stage |
|---|---|---|
| 177Lu-BetaBart | Radioantibody targeting B7-H3, conjugated to 177Lutetium | |
| NanoMab antibody technologies | Exclusive rights to anti-HER-2, anti-TROP-2, anti-PD-L1 and anti-PTK7 technology | |
| Ga-Trivehexin | Technology under exclusive license from TRIMT GmbH | |
| F-FPIA imaging agent | Imaging agent under license from Cancer Research Technology |
| Line | FY ended Jun 30, 2025 | FY ended Jun 30, 2024 |
|---|---|---|
| Revenue | $3.6 million | |
| Research and development | $27.5 million | $23.1 million |
| Net income (loss) | -$38.3 million | -$47.9 million |
| Cash from operations | -$36.6 million | -$23.0 million |
| Cash and equivalents | $29.1 million | $18.6 million |
Our latest story on this, dated Jul 23, 2026: "Radiopharm Theranostics sets $9,300,000 ATM limit, prices $4,050,001.36 ADS sale". The story links the filing or release it is based on. Read the story.
Radiopharm Theranostics Limited trades under the ticker RAD on ASX.
Radiopharm Theranostics Limited is listed on ASX. Our directory also records these other listings: NASDAQ:RADX.
The SEC Central Index Key (CIK) for Radiopharm Theranostics Limited is 1949257. Its filings are on SEC EDGAR.
3,544,216,160 shares as of 2026-06-30, per the cover page of its 20-F filed 2026-09-30.
Our directory records Radiopharm Theranostics Limited under Australia.
Our directory classifies Radiopharm Theranostics Limited as: Radiopharmaceutical drug developer. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Radiopharm Theranostics Limited is AU0000181851.
aibio.space lists Radiopharm Theranostics Limited among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as C3.
Radiopharm Theranostics Limited describes itself as a research and development company that aims to develop and commercialize platforms of radiopharmaceutical products for therapeutic and diagnostic applications in precision oncology. It says its technologies span peptides, small molecules and antibodies attached to medical quality radioisotopes, and it focuses on radiosensitive tumor types with high mortality rates.
177Lu-BetaBart: Radioantibody targeting B7-H3, conjugated to 177Lutetium
NanoMab antibody technologies: Exclusive rights to anti-HER-2, anti-TROP-2, anti-PD-L1 and anti-PTK7 technology
$3.6 million for the fiscal year ended Jun 30, 2025, as reported to the SEC.
Radiopharm Theranostics Limited reported a net loss of $38.3 million for the fiscal year ended Jun 30, 2025, and used $36.6 million of cash in operations, per its annual report to the SEC.
Set up an at-the-market program to sell shares over time. SEC Form F-3. Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form F-3. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio